Assessment of Efficacy, Safety and Tolerability of Fixed Dose Combination Wunder Eye Cream (3% Biophytex LS 8740 an 5% Proteasyl TP LS 8657) in the treatment of under Eye Dark Circles.

Assessment of Efficacy, Safety and Tolerability of Fixed Dose Combination Wunder Eye Cream (3% Biophytex LS 8740 an 5% Proteasyl TP LS 8657) in the treatment of under Eye Dark Circles. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/04/001672

Enrollment

Registered

2011-04-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- To assess the efficacy and safety of Wunder eye cream (3% Biophytex LS 8740 and 5% Proteasyl TP LS 8657) in subjects with Under eye dark circles (infraorbital hyperchromia).

Interventions

Intervention1: Wunder Eye cream: under eye dark circles Control Intervention1: None: None

Eligibility

Inclusion criteria

Inclusion criteria: ? Subjects with mild, moderate or severe under eye dark circles ? Subjects must be 18-50 years of age ? Both males and females ? Subjects with no history of glaucoma, any eye infection and with normal range of intraocular pressure ? Subjects must provide written informed consent and comply to the protocol ? Wash out period of 14 or more days prior to enrollment in case of subjects using any other skin care products.

Exclusion criteria

Exclusion criteria: ? Subjects not willing to discontinue all topical treatments for ?Under Eye? dark circles for 2 weeks prior to enrollment in study ? Hypersensitivity to any ingredients of Wunder Eye cream ? Pregnant and lactating women ? Subjects taking Concomitant therapy that might interfere with the study results ? Subjects with dermatological disorder of face that may interfere with study evaluation ? Subjects who have undergone any surgical treatment of the face ? Subjects with abnormal intraocular pressure, history of glaucoma and any eye infection on ophthalmological examination ? Concomitant topical therapy in under eye area that causes hypopigmentation includes Retinoids and Hydroquinone skin peels. ? Concomitant medicines, that cause hyper pigmentation, include Phenothiazines, Anti-malarials (Chloroquine), Phenytoin sodium, cytotoxic drugs, Sulphonamides.

Design outcomes

Primary

Measure	Time frame
To assess the efficacy and safety of Wunder eye cream (3% Biophytex LS 8740 and 5% Proteasyl TP LS 8657) in subjects with Under eye dark circles (infraorbital hyperchromia).Timepoint: 86 Days	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Mukta Sachdev

rajeshl@glenmarkpharma.com912240889082

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026